Sanofi SA (SNY)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Immunologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 12/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 0.98% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- What Is Sanofi (ENXTPA:SAN) Really Gaining From Wider Canadian Access?
- Sanofi (ENXTPA:SAN) Stock Looks Reasonable After Its Antibody Deal
- Recursion (RXRX) Enters New Growth Phase as Sanofi Kicks Off Drug Collab, Shares Soar
- Sanofi (ENXTPA:SAN) Adds AI Immunology Candidate As Fair Value Questions Persist
- Sanofi and pCPA Sign Letter of Intent for Dupixent® Across Four Indications in Dermatology and Respiratory Care
- Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
- Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?
- Update: European Commission Accepts Sanofi's Offer to Address Potential Anticompetitive Disparagement of Competing Flu Vaccine
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Sanofi SA.
Full SNY Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.